Has Mirwais Saifi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,030,194 in general payments to Mirwais Saifi, MD across 1,024 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mirwais Saifi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mirwais Saifi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mirwais Saifi, MD

Family Medicine · San Diego, CANPI 1750516753

Payments from drug & device makers

$1,030,194in general payments, 2019–2025

Across 1,024 payments — averaging $1006.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$385K
Eli Lilly$271K
AbbVie$126K
Pfizer$118K
AstraZeneca$42K
Dermira, Inc.$35K
plus $54K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	75	$384,747
Eli Lilly	16	$270,568
AbbVie(2 entities)	191	$126,065
Pfizer(2 entities)	107	$118,047
AstraZeneca	61	$41,857
Dermira, Inc.	3	$34,913
LEO Pharma AS	9	$22,528
Kowa Research Institute, Inc.	9	$13,705
Novo Nordisk	139	$2,423
Boehringer Ingelheim	47	$1,660
GSK	44	$1,568
Lilly USA, LLC	57	$1,108
Bayer	29	$1,094
Novartis	33	$761
Johnson & Johnson	9	$684
Biohaven Pharmaceuticals, Inc.	6	$547
Actelion Pharmaceuticals US, Inc.	7	$532
Abbott	7	$481
Axsome Therapeutics, Inc.	5	$472
La Jolla Pharmaceutical Company	4	$414
Daiichi Sankyo Inc.	8	$347
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	11	$339
Amgen	11	$323
Cvrx, Inc.	4	$321
Merck	9	$304
United Therapeutics Corporation	3	$302
Avanir Pharmaceuticals, Inc.	9	$282
Vanda Pharmaceuticals Inc.	17	$280
SK Life Science, Inc.	2	$249
Edwards Lifesciences	3	$229
Boston Scientific	4	$208
Lundbeck LLC	5	$205
Eisai Inc.	5	$187
Biohaven Pharmaceutical Holding Company Ltd.	8	$186
Otsuka America Pharmaceutical, Inc.	8	$181
Alnylam Pharmaceuticals Inc.	2	$169
E.r. Squibb & Sons, L.L.C.	3	$165
Gilead	2	$155
Sanofi-aventis U.S. LLC	8	$149
UCB, Inc.	1	$125
Chiesi USA, Inc.	1	$125
Aimmune Therapeutics, Inc.	1	$125
Sanofi	1	$124
Lexicon Pharmaceuticals, Inc.	1	$120
Esperion Therapeutics, Inc.	2	$109
Seqirus USA Inc	5	$102
Takeda Pharmaceuticals U.S.A., Inc.	3	$84
Kowa Pharmaceuticals America, Inc.	4	$77
Vision Quest Industries Inc.	4	$51
Ironwood Pharmaceuticals, Inc	2	$49
Corcept Therapeutics	2	$38
Neurelis, Inc.	2	$37
Sumitomo Pharma America, Inc.	3	$34
Idorsia Pharmaceuticals US Inc	2	$31
Intuity Medical Inc	1	$29
Nevro Corp.	1	$25
Astellas Pharma US Inc	1	$23
Alkermes, Inc.	1	$22
Collegium Pharmaceutical, Inc.	1	$22
Xeris Pharmaceuticals, Inc.	1	$19

How this compares

$1,030,194 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Medicare billing

Part B allowed, 2024

$278,048

Medicare patients

388

Services billed

2,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in San Diego

Daniel JohnsonSan Diego$15.7M
Stacey LayleSan Diego$14.8M
Laurie Han-ConradSan Diego$2.9M
Sheldon MorrisSan Diego$1.1M
Amina HaggagNorthridge$112.8M
Steven ReynoldsLong Beach$53M
Rizwana MohseniLake Forest$26.7M
Apinya VutikullirdCypress$14.3M
Hanid AudishSpring Valley$13.6M
Augusto FocilOxnard$12.6M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →